Marco Zarbin, MD, Ophthalmology, Newark, NJ, Saint Barnabas Medical Center

MarcoAttilioZarbinMDPhD, FACS

Ophthalmology Newark, NJ

Retinal Disease

University Ophthalmology Associates

Dr. Zarbin is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Zarbin's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Ophthalmology, 1985 - 1988
  • Dartmouth-Hitchcock Medical Center
    Dartmouth-Hitchcock Medical CenterInternship, Internal Medicine, 1984 - 1985
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1984

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1994 - 2023
  • CA State Medical License
    CA State Medical License 1990 - 2021
  • MD State Medical License
    MD State Medical License 1988 - 1991
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Inside Jersey Magazine Top Doctors Castle Connolly, 2009-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2003-2014
  • NJ.com Top Doctors Castle Connolly, 2009
  • Join now to see all

Publications & Presentations

PubMed

Press Mentions

  • The Influence of Prolongation of Interruptions of Preoperative Posturing and Other Clinical Factors on the Progress of Macula-on Retinal Detachment
    The Influence of Prolongation of Interruptions of Preoperative Posturing and Other Clinical Factors on the Progress of Macula-on Retinal DetachmentMay 13th, 2020
  • IVERIC Bio’s Zimura®, a Novel Complement C5 Inhibitor, Met Its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    IVERIC Bio’s Zimura®, a Novel Complement C5 Inhibitor, Met Its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationOctober 28th, 2019
  • Leading Ophthalmologists to Discuss the Value of IRIDEX Solutions at AAO
    Leading Ophthalmologists to Discuss the Value of IRIDEX Solutions at AAOOctober 23rd, 2018
  • Join now to see all

Grant Support

  • Neural Stability After Retinal DetachmentNational Eye Institute2012
  • Enhancing Cell Survival On Aged Bruch'S MembraneNational Eye Institute2005–2007
  • Pigment Epithelium Removal And TransplantationNational Eye Institute1994–2003
  • Pigment Epithelium Removal And TransplantationNational Eye Institute1993

Professional Memberships

Other Languages

  • French, Italian

Hospital Affiliations